NautaDutilh assists BC Partners, a leading international private equity firm, on its contemplated acquisition of a majority stake in Synthon International Holding B.V., a global market leader in the development of complex generic medicines, from its parent company Synthon Holding B.V.
BC Partners will work together with Synthon’s founder Dr. Jacques Lemmens, who will remain a shareholder of the company. Synthon will be carved out from its parent company and continues to operate under the Synthon brand. The contemplated transaction is subject to regulatory approvals and is expected to close in the coming months.
Joost den Engelsman, who heads the NautaDutilh deal team, comments: "We are delighted to assist the BC Partners team on this exciting, high pace pharmaceutical carve-out deal, including the financing, the reinvestment by the founder and the management participation. These elements enable us to employ the firm’s full private equity experience and capabilities advising the BC Partners team with a multidisciplinary team consisting of experts in Corporate M&A, Corporate Notarial, Warranty & Indemnity Insurance, Finance, Employment and Tax.”
Synthon focuses on developing, manufacturing and out-licensing complex generics and hybrid medicines for patients around the world. The company was founded by Dr. Jacques Lemmens in 1991 and has since developed a diversified base of over 200 customers serving around 100 countries worldwide.
NautaDutilh advised BC Partners on this transaction working alongside teams from Latham & Watkins and PwC. The team from NautaDutilh consists of: Joost den Engelsman, Olaf Baks and Annet Vis (Corporate M&A), Joost Kloosterman and Erik Poorthuis (W&I); Wijnand Bossenbroek, Jules van de Winckel, Florine Kuipéri (Corporate Notarial); David Vietor, Linda Tomassen and Eefke Janssen (Finance); Edward Rijnhout and Sjuul Jentjens (Tax).
The deal has been covered by media: